Form 4: Celcuity Director Leo Furcht Granted Stock Options

Director Leo Furcht of Celcuity Inc. was granted stock options to purchase 14,048 shares of common stock at an exercise price of $10.69, vesting on April 30, 2026, or the date of the Company's 2026 Annual Meeting of Stockholders.

Summary

• Leo Furcht, a director of Celcuity Inc., filed a Form 4 indicating a transaction involving derivative securities.
• On May 19, 2025, Furcht was granted stock options to purchase 14,048 shares of Celcuity's common stock.
• The exercise price of the options is $10.69 per share.
• The options vest on April 30, 2026, or the date of the Company's 2026 Annual Meeting of Stockholders, and expire on May 19, 2035.
• Furcht also signed a Power of Attorney authorizing Griffin D. Foster, Jonathan R. Zimmerman, Sheremy R. Anderson, and Amra Hoso to act on his behalf in matters related to SEC filings.

Sentiment

Score: 7

Explanation: The document reflects a standard corporate action (stock option grant) and the sentiment is neutral to slightly positive as it incentivizes a key member of the company.

Positives

• The granting of stock options to a director aligns their interests with those of the shareholders.
• The vesting schedule encourages long-term commitment from the director.

Future Outlook

The document does not contain specific forward-looking statements beyond the vesting and expiration dates of the stock options.

Industry Context

Stock option grants are a common practice in the biotechnology industry to incentivize and retain key personnel, aligning their interests with the long-term success of the company. This is a standard compensation practice.

Comparison to Industry Standards

• Stock option grants are a common form of compensation for directors in publicly traded companies, particularly in the biotech sector.
• The vesting schedule of approximately one year is fairly standard.
• The exercise price is set at the market price on the grant date, which is typical.
• Comparable companies such as Exact Sciences or Guardant Health also utilize stock options as part of their director compensation packages.

Stakeholder Impact

• The stock option grant could potentially dilute existing shareholders if the options are exercised.
• The grant incentivizes the director to work towards increasing shareholder value.

Key Dates

Keywords

stock options, Form 4, Celcuity, director, Furcht, securities, ownership, transaction